Pediatrics

The trial met both its primary efficacy and key secondary endpoints.

Specialists discuss diagnostic technologies, treatment strategies, and research that are improving outcomes for young patients.

The decision follows results from the Phase 3 STAR trial, among the largest global studies of low-dose atropine in pediatric myopia.

The trial results show promising for the evaluated gene therapy for the treatments of LCA, showing significant vision improvements in pediatric patients.

A study reveals atropine induces less myopic refraction than cyclopentolate in preschoolers, impacting premyopia diagnosis and intervention strategies.

Considering rapid increases in myopia, authors conducted a longitudinal cohort study of twins and their parents with the goal of exploring the intergenerational changes in the myopia epidemic in China.

IVMED-85 is a preservative-free prescription eye drop designed to prevent myopia progression in children.

As myopia becomes a worldwide epidemic, the upcoming Paris workshop on September 8, 2025, will convene global leaders to discuss strategies, research priorities, and new treatment pathways.

Ocular salvage and preservation of vision are essentially dependent on early diagnosis, and several studies have been conducted to identify the factors leading to delayed diagnosis at presentation.

Authors noted it may be worthwhile to explore whether oral methylphenidate affects myopia by influencing dopamine levels

A Chinese study reveals that secondhand smoke exposure significantly increases the risk of early-onset myopia in children

Compared with penicillin, investigators reported no significant differences in the incidence of ophthalmologic manifestations among patients treated with ceftriaxone.

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.

IVMED-85 is a preservative-free, non-atropine daily drop that slows myopia progression by strengthening scleral and corneal collagen crosslinks via LOX activation.

The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1,310 nm that can scan at a speed of 50,000 A-scan/second.

ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.

Machine learning algorithms enhance retinopathy of prematurity screening using smartphone images, expanding access in low-resource settings and easing pediatric ophthalmologist workloads.

The clearance expands its existing label from patients aged 4 to 7 years to patients aged 4 to under 13 years.

Chinese researchers reveal that low-level red light therapy may control myopia in children but raises concerns about retinal damage and cone density reduction.